Media stories about Cytokinetics (NASDAQ:CYTK) have been trending somewhat positive recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cytokinetics earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.4750392385466 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
Shares of Cytokinetics (CYTK) traded down $0.30 during midday trading on Monday, hitting $9.30. The stock had a trading volume of 235,374 shares, compared to its average volume of 310,231. The company has a debt-to-equity ratio of 0.14, a current ratio of 7.60 and a quick ratio of 7.60. Cytokinetics has a one year low of $7.00 and a one year high of $17.20. The company has a market cap of $511.33, a P/E ratio of -5.60 and a beta of 1.61.
Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($0.60) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.64) by $0.04. Cytokinetics had a negative return on equity of 62.64% and a negative net margin of 172.27%. The company had revenue of $6.18 million during the quarter, compared to the consensus estimate of $5.35 million. equities analysts predict that Cytokinetics will post -2.4 EPS for the current fiscal year.
A number of research analysts have weighed in on CYTK shares. Morgan Stanley restated an “overweight” rating and issued a $17.00 price target (down from $25.00) on shares of Cytokinetics in a research note on Wednesday, November 22nd. Cantor Fitzgerald downgraded Cytokinetics from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $21.00 to $10.00 in a research note on Wednesday, November 22nd. HC Wainwright decreased their price target on Cytokinetics from $26.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, November 21st. Seaport Global Securities restated a “buy” rating and issued a $24.00 price target on shares of Cytokinetics in a research note on Friday, October 6th. Finally, ValuEngine downgraded Cytokinetics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the stock. Cytokinetics currently has a consensus rating of “Buy” and a consensus target price of $17.91.
In related news, insider Caryn Gordon Mcdowell sold 4,260 shares of Cytokinetics stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $12.94, for a total transaction of $55,124.40. Following the completion of the sale, the insider now directly owns 17,982 shares of the company’s stock, valued at approximately $232,687.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Robert I. Blum sold 5,000 shares of Cytokinetics stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $13.51, for a total value of $67,550.00. Following the sale, the chief executive officer now directly owns 70,180 shares of the company’s stock, valued at $948,131.80. The disclosure for this sale can be found here. Insiders have sold a total of 19,290 shares of company stock valued at $245,084 over the last quarter. 7.20% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/22/cytokinetics-cytk-getting-somewhat-positive-news-coverage-analysis-finds.html.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.